FEATURED EDITORIAL
Don’t reinvent the wheel — adapt it. Locate before you correct, because where a failure appears isn’t necessarily where it gets fixed.
- Comparing Advanced Modality Needs, Part 1: Manufacturing
- Sustainability In Manufacturing: Power And Digital Twins
- My CDMO Is A Constellation of Unified Skills. Is Yours?
- Developing Your Vapor Phase Hydrogen Peroxide Cycle
- The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
- Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
- How To Build A Medicine When Someone Is Waiting For A Dose
GUEST COLUMNISTS
-
The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
A Beroe analysis of 2026 pharma AI deals shows discovery still dominates, suppliers are consolidating, and clinical development is the next AI sourcing frontier.
-
Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
Determining whether a drug manufacturing environment is stable, drifting, or developing a recurring loss-of-control signal requires integrated trend evaluation.
-
What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.
-
How Is Your Glass Supplier Adapting To Europe's Energy Crisis?
Europe's glass manufacturers, including those making pharmaceutical lab glassware, have experienced a series of energy shocks. Many have adopted sustainability practices.
-
The EU Overhauls Pharma Laws: What You Need To Know
On Sept. 18, the Council of the EU published the almost-final text of a major overhaul of the EU pharmaceutical laws. The final binding text is expected to be published very soon.
-
September 2026 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
-
Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
Geopolitical shocks are reshaping outsourced pharmaceutical testing. Learn how procurement teams can strengthen resilience and protect continuity.
PHARMA OUTSOURCING WHITE PAPERS
-
Controlling Plasmid Forms For LVV And mRNA Production
Plasmid monomer and multimer forms affect downstream applications differently. Learn how optimized analytics and control strategies support LVV performance and mRNA production quality.
-
Integrating Analytical And Process Development For Cell Therapies
Integrating process development, RNA sequencing, and flow cytometry guides media selection, tracks phenotypic shifts, and accelerates cell therapy commercialization and regulatory progress.
-
Designing, Selecting, And Developing Bioconjugates For Clinical Success
Accelerate the development of complex bioconjugates to unlock new possibilities for targeted therapies and advance the next generation of precision medicine.
-
Difficult-To-Purify And Difficult-To-Filter Small Molecules
Poor filterability and stubborn impurities often trace back to the same molecular features, which changes how development teams approach scale-up for larger, structurally complex small molecules.
-
Choosing The Right CDMO For Substance Development And Manufacturing
Controlled substance programs demand licensing, closed-system custody, and inspection history well beyond GMP. Sponsors weighing partners must test technical depth against compliance infrastructure.
-
Advancing ADCs: From Concept To Commercialization
ADC programs move fastest when payload-linker strategy, route design, conjugation, and drug product are planned together, with timelines and scale-up capacity shaping choices from the earliest development stages.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
- From Early Development To Commercial Launch: An End-To-End Partnership
- Unlocking Higher Complex Capsule Yields Through More Efficient Manufacturing
- Selecting The Right Chromatography Strategy
- Optimizing Particle Properties For Difficult Small Molecules
- Turning A "Brick Dust" Compound Into A Clinically Viable Oral Formulation
NEWSLETTER ARCHIVE
REPORTING
EDITORIAL COLLECTIONS
Take a closer look at the decisions shaping biopharma outsourcing. Our Editorial Collections examine how organizations select CDMOs, manage external relationships, transfer processes, and weigh the business realities of outsourced development and manufacturing.
More Editorial CollectionsPRODUCTS & SERVICES
ON-DEMAND WEBINARS
- Planning For Scale From The Start: Where Early Development Decisions Create Commercial Risk
- Decoding Biologic Performance: Combining SPR And Cell-Based Assays To Drive Development Decisions
- Rethinking Facility Design For The Reality Of Complex Biologics
- Accelerating Late-Stage Biologics Through Platform-Based Manufacturing
- From iPSC Starting Material to Scalable GMP Manufacturing

